Bizarre Patents
A fork with timer for providing a cue to a user after an elapsed period of time for indicating that another bite of food using the fork may be taken.
PatentStorm News
Make the Most of Our Site
See this month's Top Inventors and Most Cited Patents.
Stay on top of the latest innovations by subscribing to an RSS feed.
Registered users: Manage your profile.
| Number | Title | Issue Date |
| 8436149 | Crystalline anti-hTNFalpha antibodies The present invention relates to a batch crystallization method for crystallizing an anti-hTNFalpha antibody which allows the production of said antibody on an industrial scale; antibody crystals as obtained according to said method; compositions containing said cry... | 05/07/2013 |
| 8404819 | Crystalline anti-human IL-12 antibodies The invention relates to batch crystallization methods for crystallizing an anti-hIL-12 antibody that allows the production of the antibody on an industrial scale, antibody crystals obtained according to the methods, compositions containing the crystals, and methods... | 03/26/2013 |
| 8404818 | Monoclonal antibodies against orthopoxviruses The present invention relates to monoclonal antibodies that bind or neutralize Orthopoxviruses. The invention provides such antibodies, fragments of such antibodies retaining B5 or A33 binding ability, fully human antibodies retaining B5 or A33 binding ability, and ... | 03/26/2013 |
| 8357781 | Neuroactive fragments of APP The application provides novel neuroactive fragments of human amyloid precursor protein (APP). The fragments include sequence from the Aβ region of APP but also extend upstream. The fragments are soluble in aqueous solution most bands are about 10 kDa and above and... | 01/22/2013 |
| 8263747 | Therapeutic monoclonal antibodies that neutralize botulinum neurotoxins This invention provides antibodies that specifically bind to and neutralize botulinum neurotoxin type A (BoNT/A) and the epitopes bound by those antibodies. The antibodies and derivatives thereof and/or other antibodies that specifically bind to the neutralizing epi... | 09/11/2012 |
| 8222374 | IL-21 antagonists Monoclonal antibodies are identified that bind the IL-21 protein. These antibodies are used to identify regions of the IL-21 protein to where binding neutralizes IL-21 activity. Hybridomas and methods of producing anti-IL-21 monoclonal antibodies are described. The ... | 07/17/2012 |
| 8168760 | Crystalline anti-human IL-12 antibodies The invention relates to batch crystallization methods for crystallizing an anti-hIL-12 antibody that allows the production of the antibody on an industrial scale, antibody crystals obtained according to the methods, compositions containing the crystals, and methods... | 05/01/2012 |
| 8143379 | Human monoclonal antibodies to CTLA-4 In accordance with the present invention, there are provided fully human monoclonal antibodies against human cytotoxic T-lymphocyte antigen 4 (CTLA-4). Nucleotide sequences encoding and amino acid sequences comprising heavy and light chain immunoglobulin molecules, ... | 03/27/2012 |
| 8133981 | Therapeutic use of anti-CS1 antibodies The present invention is directed to antagonists of CS1 that bind to and neutralize at least one biological activity of CS1. The invention also includes a pharmaceutical composition comprising such antibodies or antigen-binding fragments thereof. The present inventi... | 03/13/2012 |
| 8106163 | Compositions and methods of use for therapeutic antibodies The present invention relates to antibodies that specifically bind to the BAFF receptor (BAFFR). The invention more specifically relates to specific antibodies that are BAFFR antagonists with in vivo B cell depleting activity and compositions and methods of use for ... | 01/31/2012 |
| 8088898 | Therapeutic use of anti-CS1 antibodies The present invention is directed to antagonists of CS1 that bind to and neutralize at least one biological activity of CS1. The invention also includes a pharmaceutical composition comprising such antibodies or antigen-binding fragments thereof. The present inventi... | 01/03/2012 |
| 8039597 | Antibodies and related molecules that bind to 24P4C12 proteins Antibodies and molecules derived therefrom that bind to 24P4C12 protein and variants thereof, are described wherein 24P4C12 exhibits tissue specific expression in normal adult tissue, and is aberrantly expressed in the cancers listed in Table I. Consequently, 24P4C1... | 10/18/2011 |
| 8034906 | Crystalline anti-hTNFalpha antibodies The present invention relates to a batch crystallization method for crystallizing an anti-hTNFalpha antibody which allows the production of said antibody on an industrial scale; antibody crystals as obtained according to said method; compositions containing said cry... | 10/11/2011 |
| 8008449 | Human monoclonal antibodies to programmed death 1 (PD-1) and methods for treating cancer using anti-PD-1 antibodies alone or in combination with other immunotherapeutics The present invention provides isolated monoclonal antibodies, particularly human monoclonal antibodies, that specifically bind to PD-1 with high affinity. Nucleic acid molecules encoding the antibodies of the invention, expression vectors, host cells and methods fo... | 08/30/2011 |
| 8008450 | Therapeutic use of anti-CS1 antibodies The present invention is directed to antagonists of CS1 that bind to and neutralize at least one biological activity of CS1. The invention also includes a pharmaceutical composition comprising such antibodies or antigen-binding fragments thereof. The present inventi... | 08/30/2011 |
| 7943743 | Human monoclonal antibodies to programmed death ligand 1 (PD-L1) The present disclosure provides isolated monoclonal antibodies, particularly human monoclonal antibodies that specifically bind to PD-L1 with high affinity. Nucleic acid molecules encoding the antibodies of this disclosure, expression vectors, host cells and methods... | 05/17/2011 |
| 7943744 | ICAM-1 binding antibodies The invention provides binding molecules, including antibody molecules which selectively bind to a cell surface antigen of a target cell, and wherein the binding molecules, on binding the cell surface antigen, induce apoptosis of the target cell. There is also provi... | 05/17/2011 |
| 7943745 | Anti-CD98 antibody A human antibody or a functional fragment thereof having specific binding ability to CD98 which is derived from the cell membrane of cancer cells and is in the form of a complex with a protein having an amino acid transporter activity (for example, LAT1) is disclose... | 05/17/2011 |
| 7923539 | IL-21 antagonists Monoclonal antibodies are identified that bind the IL-21 protein. These antibodies are used to identify regions of the IL-21 protein to where binding neutralizes IL-21 activity. Hybridomas and methods of producing anti-IL-21 monoclonal antibodies are described. The ... | 04/12/2011 |
| 7910706 | Humanized neutralizing antibodies against hemolytic uremic syndrome Novel human monoclonal antibodies derived from a transgenic mouse are disclosed as well as a process for the preparation of the novel monoclonals and a therapeutic method of treating an individual for hemolytic uremic syndrome or of protecting an individual against ... | 03/22/2011 |
| 7893217 | Isolated human antibodies that bind epitopes on RG1 The present invention relates to novel human extracellular matrix polypeptides, designated RG1, polynucleotides encoding the polypeptides, methods for producing the polypeptides, expression vectors and genetically engineered host cells for expression of the polypept... | 02/22/2011 |
| 7879984 | Human antibodies to human CD20 and method of using thereof A human antibody or antigen-binding fragment of an antibody that specifically binds human CD20 and is capable of inducing complement dependent cytotoxicity (CDC), and is capable of increasing symptom free survival time between about 2-fold to about 9-fold or more, r... | 02/01/2011 |
| 7807798 | Human monoclonal antibodies to epidermal growth factor receptor In accordance with the present invention, there are provided fully human monoclonal antibodies against human epidermal growth factor receptor (EGF-r). Nucelotide sequences encoding and amino acid sequences comprising heavy and light chain immunoglobulin molecules, p... | 10/05/2010 |
| 7754859 | Targeted binding agents directed to PDGFR-alpha and uses thereof Targeted binding agents directed to the antigen PDGFR-alpha and uses of such agents are disclosed herein. More specifically the invention relates to fully human monoclonal antibodies directed to the antigen PDGFR-alpha and uses of these antibodies. Aspects of the in... | 07/13/2010 |
| 7728114 | Anti-CD3 antibodies and methods of use thereof The present invention is related to antibodies directed to the antigen CD3 and uses of such antibodies. In particular, the present invention provides fully human monoclonal antibodies directed to CD3. Nucleotide sequences encoding, and amino acid sequences comprisin... | 06/01/2010 |
| 7718776 | Human anti-OPGL neutralizing antibodies as selective OPGL pathway inhibitors Monoclonal antibodies and hybridomas producing them that interact with osteoprotegerin ligand (OPGL) are provided. Methods of treating osteopenic disorders by administering a pharmaceutically effective amount of antibodies to OPGL are also provided. Methods of detec... | 05/18/2010 |
| 7709610 | Therapeutic use of anti-CS1 antibodies The present invention is directed to antagonists of CS1 that bind to and neutralize at least one biological activity of CS1. The invention also includes a pharmaceutical composition comprising such antibodies or antigen-binding fragments thereof. The present inventi... | 05/04/2010 |
| 7638606 | Antibodies that bind interleukin-4 receptor The present invention relates to antibodies that bind to the IL-4 receptor, fragments, muteins, and derivatives of such antibodies, nucleic acids encoding such antibodies, fragments, muteins and derivatives, and methods of making and using such antibodies, fragments... | 12/29/2009 |
| 7638605 | Fully human antibodies directed against the human insulin-like growth factor-1 receptor This invention relates to human antibodies that bind to human insulin-like growth factor-1 receptor (IGF-IR), to derivatives of these antibodies (Fabs, single chain antibodies, bi-specific antibodes, or fusion proteins), and to uses of the antibodies and derivatives... | 12/29/2009 |
| 7605238 | Human CTLA-4 antibodies and their uses The present invention provides human sequence antibodies against human CTLA-4 and methods of treating human diseases, infections and other conditions using these antibodies. ... | 10/20/2009 |
| 7572897 | Antibodies against insulin-like growth factor I receptor and uses thereof Antibodies against insulin like growth factor I receptor (IGF-IR), methods for their production, pharmaceutical compositions containing said antibodies, and uses for such antibodies are disclosed. Antibodies against IGF-IR are implicated in antitumor therapy. ... | 08/11/2009 |
| 7566772 | Antibodies against interleukin-1β Antibodies directed to the antigen IL-1β and uses of such antibodies are described. In particular, fully human monoclonal antibodies directed to the antigen IL-1β. Nucleotide sequences encoding, and amino acid sequences comprising, heavy and light chain immunoglob... | 07/28/2009 |
| 7563874 | Therapeutic monoclonal antibodies that neutralize botulinum neurotoxins This invention provides antibodies that specifically bind to and neutralize botulinum neurotoxin type A (BoNT/A) and the epitopes bound by those antibodies. The antibodies and derivatives thereof and/or other antibodies that specifically bind to the neutralizing epi... | 07/21/2009 |
| 7498420 | Antibodies to c-Met The present invention relates to antibodies including human antibodies and antigen-binding portions thereof that specifically bind to c-Met, preferably human c-Met, and that function to inhibit c-Met. The invention also relates to human anti-c-Met antibodies and ant... | 03/03/2009 |
| 7491803 | Human anti-human interleukin-18 antibody, fragment thereof and method for using same A human-derived human anti-human IL-18 antibody of the present invention is an antibody against human IL-18, the antibody including: an H-chain complementarity determining region consisting of (a) a polypeptide consisting of amino-acid sequences represented by SEQ I... | 02/17/2009 |
| 7488805 | Apoptosis proteins The present invention is directed to novel apoptosis polypeptides such as the Apop1, Apop2, and Apop3 proteins and related molecules which are involved in modulating apoptosis and to nucleic acid molecules encoding those polypeptides. Also provided herein are vector... | 02/10/2009 |
| 7488806 | Human antibodies to human delta like ligand 4 An isolated human antibody or a fragment of a human antibody which specifically binds to human delta-like ligand 4 (hDll4) and blocks hDll4 binding to a Notch receptor. The human anti-hDll4 antibody or antibody fragment binds hDll4 with an affinity of 300 pM or bett... | 02/10/2009 |
| 7482436 | Human antihuman interleukin-6 antibody and fragment of antibody A substance effective for treating immunopathy where interleukin 6 (IL-6) is involved is provided. A human anti-human IL-6 antibody and a human anti-human IL-6 antibody fragment having a high affinity to human IL-6 were obtained using phage antibody technique. The a... | 01/27/2009 |
| 7442373 | Antibodies against protective antigen and methods of use for passive immunization and treatment of anthrax A highly efficient method for generating human antibodies using recall technology is provided. In one aspect, human antibodies which are specific to the anthrax toxin are provided. In one aspect, human peripheral blood cells that have been pre-exposed to anthrax tox... | 10/28/2008 |
| 7442772 | Antibodies to PRO361 polypeptide The present invention is directed to secreted and transmembrane polypeptides and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising... | 10/28/2008 |
